Sartorius Stedim Biotech SA

DIM: XPAR (FRA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
#@!LOCK|<TLOCK|$FrrCB

Sartorius Stedim Earnings: Consumables Strength Offsets Equipment Softness; Shares Undervalued

Sartorius Stedim reported its preliminary full-year 2025 results with 9.6% growth in constant currencies and in line with company-compiled consensus, while the adjusted EBITDA margin of 30.8% fell short.

Sponsor Center